Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Purchases of Investments

Cash used to buy marketable securities and other investments.

Novo Nordisk A/SNYSE: NVO

Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026

Purchases of investments declines year over year

Q2 FY2026 purchases of investments of DKK 94M (cash outflow) fell 83.8% year over year, ahead of the -98.7% change in trailing-twelve-month purchases of investments. Over 3 fiscal years it compounded at -58.0% a year.

Context

  • Purchases of investments amounted to 0.2% of revenue in FY2025, down 6.6 pp from a year earlier.
  • Purchases of investments grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -83.8% holds above the trailing-twelve-month pace of -98.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-DKK 94M— QoQ
Last fiscal yearDec 2025
-DKK 723M-96.4% YoY
LTMJun 2026
-DKK 120M-98.7% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-83.8%——
1 year-96.4%——
3-year CAGR-58.0%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

DKK · from the cash flow

Latest · FY2025
(723M) DKK
Year-over-year change
+96.4%

Purchases of Investments vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -98.7% is the lowest of 7, against a peer median of +1.1%.
  • Purchases of investments amounts to 0.0% of revenue for NVO, versus a peer median of 1.1%.
NVO Competitors
Purchases of Investments for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$10.63B USD-40.2%-27.7%16.7%
SNYSanofiLTM Jun 2026€1.86B EUR—+185.6%3.8%
JNJJohnson & JohnsonLTM Sep 2026$1.46B USD+55.6%-69.5%1.5%
MRKMerck & Co., Inc.LTM Jun 2026$933M USD-46.7%+0.1%1.4%
LLYEli Lilly and CompanyLTM Jun 2026$881.1M USD+4.3%-3.0%1.1%
ABBVAbbVie Inc.LTM Jun 2026$279M USD+282.2%-71.0%0.4%
AZNAstraZeneca PLCLTM Sep 2026$213.22M USD-2.2%+12.9%0.3%
NVONovo Nordisk A/SLTM Jun 2026DKK 120M DKK-98.7%-58.0%0.0%
GSKGSK plcLTM Jun 2026£69.01M GBP—-20.2%0.2%
AMGNAmgen Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding NVO) —+1.1%-11.6%1.1%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.